{"doi":"10.3390/medsci12030048","title":"Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression","abstract":"<jats:p>The treatment landscape for metastatic renal cell carcinoma (RCC) has advanced significantly with first-line immunotargeted therapy combinations. However, no statistically significant differences were observed in the cohort of patients with favorable risk and some oncologists continue to use sunitinib in these patients. PD-L1 expression has emerged as a negative prognostic factor in RCC, particularly in sunitinib-treated patients, where higher PD-L1 levels are linked to worse outcomes. This article discusses the potential risks associated with the use of sunitinib in PD-L1-positive patients.</jats:p>","journal":"Medical Sciences","year":2024,"id":624236,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1545026,"name":"Ilya Tsimafeyeu","orcid":"0000-0002-7357-0392","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression","abstract":"<jats:p>The treatment landscape for metastatic renal cell carcinoma (RCC) has advanced significantly with first-line immunotargeted therapy combinations. However, no statistically significant differences were observed in the cohort of patients with favorable risk and some oncologists continue to use sunitinib in these patients. PD-L1 expression has emerged as a negative prognostic factor in RCC, particularly in sunitinib-treated patients, where higher PD-L1 levels are linked to worse outcomes. This article discusses the potential risks associated with the use of sunitinib in PD-L1-positive patients.</jats:p>","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39311161","pmcid":"PMC11417775","openalex_id":"https://openalex.org/W4402524721","authors":[],"funders":[],"total_grants":0,"fwci":0.8628,"citation_percentile":0.7455966,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2076-3271/12/3/48/pdf?version=1726206056","host_type":"journal"},{"url":"https://www.mdpi.com/2076-3271/12/3/48/pdf?version=1726206056","host_type":"publisher"},{"url":"https://www.mdpi.com/2076-3271/12/3/48/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/medsci12030048","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39311161","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11417775","host_type":"repository"},{"url":"https://doaj.org/article/8572d512128a4fb1a1e850a305e781b9","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11417775/pdf/medsci-12-00048.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11417775","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11417775?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Renal cell carcinoma treatment","Cancer Immunotherapy and Biomarkers","Pancreatic and Hepatic Oncology Research"],"mesh_terms":["Sunitinib","Antineoplastic Agents","Carcinoma, Renal Cell","Humans","Kidney Neoplasms","Prognosis","B7-H1 Antigen"],"keywords":["Sunitinib","Medicine","Renal cell carcinoma","Internal medicine","Oncology","Cohort","First line","First-line Therapy","Pd-l1 Expression","Metastic Renal Cell Carcinoma","Immunotargeted Therapy","Favorable Imdc Risk"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T03:08:42.909085Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}